Allantoin

Identification

Summary

Allantoin is an ingredient used in skin care products to relieve irritation and protect minor cuts, scrapes, and burns.

Brand Names
Allegra Cooling Relief Anti-itch, Anbesol Cold Sore Therapy, Mederma Advanced Scar
Generic Name
Allantoin
DrugBank Accession Number
DB11100
Background

Allantoin is a substance that is endogenous to the human body and also found as a normal component of human diets Label. In healthy human volunteers, the mean plasma concentration of allantoin is about 2-3 mg/l. During exercise, the plasma allantoin concentration rapidly increases about two fold and remains elevated Label. In human muscle, urate is oxidized to allantoin during such exercise Label. The concentration of allantoin in muscles increases from a resting value of about 5000 ug/kg to about 16000 ug/kg immediately after short-term exhaustive cycling exercise Label.

More specifically, allantoin is a diureide of glyoxylic acid that is produced from uric acid. It is a major metabolic intermediate in most organisms. Allantoin is found in OTC cosmetic products and other commercial products such as oral hygiene products, in shampoos, lipsticks, anti-acne products, sun care products, and clarifying lotions 4. Allantoin has also demonstrated to ameliorate the wound healing process in some studies 1.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 158.1154
Monoisotopic: 158.043990078
Chemical Formula
C4H6N4O3
Synonyms
  • (2,5-Dioxo-4-imidazolidinyl)urea
  • 2,5-Dioxo-4-imidazolidinyl-urea
  • 4-ureido-2,5-imidazolidinedione
  • 5-Ureido-2,4-imidazolidindione
  • 5-Ureidohydantoin
  • Alantoína
  • Allantoin
  • Glyoxyldiureide
  • N-(2,5-Dioxo-4-imidazolidinyl)urea

Pharmacology

Indication

Allantoin is commonly applied in a variety of topical vehicles or applications such as cosmetic creams, toothpastes, mouthwashes, shampoos, lipsticks, anti-acne products, and lotions 4 for the purpose of moisturizing skin, enhancing the smoothness of skin, stimulating the healing of wounds, and soothing irritated skin 4,Label.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatScarringCombination Product in combination with: Onion (DB10548), Heparin (DB01109)•••••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

There is no well controlled and appropriate data that can formally substantiate the pharmacodynamic properties of allantoin Label. Nevertheless, ongoing studies suggest that allantoin possesses moisturizing and keratolytic effects, as well as abilities to increase the water content of the extracellular matrix and enhance the desquamation of upper layers of dead skin cells, all of which are activities that can promote cell proliferation and facilitate wound healing 1.

Mechanism of action

There is no well controlled data that can formally substantiate the method of action Label. However, ongoing studies suggest that there may exist a histological wound healing profile induced by allantoin in rats that leads to the amelioration and fastening of the reestablishment of normal skin 1. This facilitation of wound healing is supported by observations that wounds inflicted to rat subjects to which topical allantoin preparations were applied histologically demonstrated increased vasodilation, presence of inflammatory exudates, number of inflammatory cells, angiogenesis, fibroblast proliferation, and increased collagen deposition when compared to rat subjects with wounds that did not receive any allantoin administration 1.

Absorption

In studies on human subjects, a recovery of 19% and 34% of allantoin in the urine was observed but only in two individuals and only after the administration of massive doses of allantoin 5. After intravenous administration, recovery in the urine was practically quantitative with doses of 75 to 600 mgm in the human model 5. After 240 mgm, excretion continued for 72 hours in human subjects and the results were similar in regards to subcutaneous injection 5.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Uricase is the enzyme that possesses the functionality to convert uric acid to allantoin. Considering humans do not possess any endogenous uricase, uric acid is the only final breakdown product in the purine degradation of unwanted waste product purine nucleotides 5. The presence of allantoin in human urine is subsequently the result of non-enzymatic processes on uric acid with reactive oxygen species 3. Such non-enzymatic processes are consequently potentially suitable biomarkers for measuring oxidative stress in chronic illnesses and aging 3. Furthermore, as allantoin is found endogenously and is part of basic, natural metabolic pathways, no accumulation is expected of it Label. Additionally, allantoin is not believed to be metabolized to a measurable extent in humans and animals Label.

Route of elimination

Urinary clearance is the predominant excretion route Label.

Half-life

When studied in cattle, sheep, and horses, the half-life of allantoin is in the range of 1 to 2.5 hours Label.

Clearance

Some studies suggest that the average renal clearance of allantoin in normal, healthy human subjects is approximately 123 cc per minute 2. It is generally agreed upon that exogenously administered allantoin is rapidly excreted Label.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

No studies on repeated dose toxicity and reproductive toxicity have been submitted. Moreover, studies show that the tumor incidence in allantoin treated animals did not differ largely from that found in untreated controls. As a result, further or additional toxicity, mutagenicity, or carcinogenicity tests are not required in view of the endogenous nature of allantoin and the general lack of overall toxicity Label.

Finally, as allantoin is a normal component of the diet in humans and is a substance of endogenous origin present in the body of humans, it is generally recognized as being a safe substance for humans Label.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Asparaginase Erwinia chrysanthemiThe therapeutic efficacy of Allantoin can be increased when used in combination with Asparaginase Erwinia chrysanthemi.
Asparaginase Escherichia coliThe therapeutic efficacy of Allantoin can be increased when used in combination with Asparaginase Escherichia coli.
Beclomethasone dipropionateThe therapeutic efficacy of Allantoin can be increased when used in combination with Beclomethasone dipropionate.
CarbamazepineThe therapeutic efficacy of Allantoin can be increased when used in combination with Carbamazepine.
CiclesonideThe therapeutic efficacy of Allantoin can be increased when used in combination with Ciclesonide.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
12 Hour HealingOintment0.5 g/100gTopicalSkinfix, Inc.2017-05-022020-01-03US flag
12 Hour HealingOintment0.5 g/100gTopicalCanadian Custom Packaging Company2017-05-022017-11-17US flag
12 Hour MiracleOintment0.5 g/100gTopicalSkinfix, Inc.2015-05-232020-01-03US flag
28 Remedy Aqua Brightening PeelingGel0.05 g/100mLTopicalNoTS Co.,Ltd2016-01-022018-12-01US flag
3ce Fixer and Mascara BlackLiquid0.006 g/6.6gTopicalNanda Co., Ltd.2016-08-20Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
3M Nexcare Cold Sore TreatmentAllantoin (10 mg/1g) + Benzocaine (50 mg/1g)OintmentTopical3M Company2008-02-202015-09-30US flag
4JointzAllantoin (0.025 g/100g) + Eucalyptus oil (4 g/100g) + Tannic acid (5 g/100g)CreamTopicalArp(usa) Pty Ltd2017-01-312018-04-05US flag
A.H.c Cotton 100 Mask Multi PeptideAllantoin (0.025 g/25mL) + Adenosine (0.01 g/25mL) + Nicotinamide (0.05 g/25mL)PatchTopicalCarver Korea Co.,Ltd.2017-09-202018-12-01US flag
A.H.c Cotton 100 Mask Skin CeramideAllantoin (0.025 g/25mL) + Adenosine (0.01 g/25mL) + Nicotinamide (0.05 g/25mL)PatchTopicalCarver Korea Co.,Ltd.2017-09-052018-12-01US flag
A.H.c Cotton 100 Mask Soy IsoflavoneAllantoin (0.025 g/25mL) + Adenosine (0.01 g/25mL) + Nicotinamide (0.05 g/25mL)PatchTopicalCarver Korea Co.,Ltd.2017-09-142018-12-01US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
28 Remedy Aqua Brightening PeelingAllantoin (0.05 g/100mL)GelTopicalNoTS Co.,Ltd2016-01-022018-12-01US flag
3ce Fixer and Mascara BlackAllantoin (0.006 g/6.6g)LiquidTopicalNanda Co., Ltd.2016-08-20Not applicableUS flag
3ce Fixer and Mascara BrownAllantoin (0.006 g/6.6g)LiquidTopicalNanda Co., Ltd.2016-08-20Not applicableUS flag
A.H.c Cotton 100 Mask Multi PeptideAllantoin (0.025 g/25mL) + Adenosine (0.01 g/25mL) + Nicotinamide (0.05 g/25mL)PatchTopicalCarver Korea Co.,Ltd.2017-09-202018-12-01US flag
A.H.c Cotton 100 Mask Skin CeramideAllantoin (0.025 g/25mL) + Adenosine (0.01 g/25mL) + Nicotinamide (0.05 g/25mL)PatchTopicalCarver Korea Co.,Ltd.2017-09-052018-12-01US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as imidazoles. These are compounds containing an imidazole ring, which is an aromatic five-member ring with two nitrogen atoms at positions 1 and 3, and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Imidazoles
Alternative Parents
Isoureas / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Imines / Hydrocarbon derivatives
Substituents
Aliphatic heteromonocyclic compound / Azacycle / Carboximidamide / Carboximidic acid derivative / Hydrocarbon derivative / Imidazole / Imine / Isourea / Organic 1,3-dipolar compound / Organic nitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
ureas, imidazolidine-2,4-dione (CHEBI:15676) / a small molecule (S-ALLANTOIN)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
344S277G0Z
CAS number
97-59-6
InChI Key
POJWUDADGALRAB-UHFFFAOYSA-N
InChI
InChI=1S/C4H6N4O3/c5-3(10)6-1-2(9)8-4(11)7-1/h1H,(H3,5,6,10)(H2,7,8,9,11)
IUPAC Name
(2,5-dioxoimidazolidin-4-yl)urea
SMILES
NC(=O)NC1NC(=O)NC1=O

References

General References
  1. Araujo LU, Grabe-Guimaraes A, Mosqueira VC, Carneiro CM, Silva-Barcellos NM: Profile of wound healing process induced by allantoin. Acta Cir Bras. 2010 Oct;25(5):460-6. [Article]
  2. FRIEDMAN M, MYERS SO, ABRAHM PM: Allantoin clearance as a measure of glomerular filtration rate in man. Proc Soc Exp Biol Med. 1947 Dec;66(3):522. [Article]
  3. Kand'ar R, Zakova P: Allantoin as a marker of oxidative stress in human erythrocytes. Clin Chem Lab Med. 2008;46(9):1270-4. doi: 10.1515/CCLM.2008.244. [Article]
  4. Thornfeldt C: Cosmeceuticals containing herbs: fact, fiction, and future. Dermatol Surg. 2005 Jul;31(7 Pt 2):873-80; discussion 880. [Article]
  5. Toxnet Toxicology Data Network: Allantoin [Link]
  6. TITCK Product Information: Noskar (allium cepa extract/allantoin/heparin sodium) topical gel [Link]
Human Metabolome Database
HMDB0000462
KEGG Drug
D00121
KEGG Compound
C01551
PubChem Substance
347911116
ChemSpider
199
RxNav
508
ChEBI
15676
ChEMBL
CHEMBL593429
Wikipedia
Allantoin
FDA label
Download (115 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentPostoperative paralytic ileus1
2CompletedTreatmentEpidermolysis Bullosa (EB)1
2CompletedTreatmentLeg Injuries and Disorders / Venous Leg Ulcer (VLU)1
2RecruitingTreatmentChildren, Adult / Impaired Glucose Tolerance1
2, 3RecruitingTreatmentDiabetic Foot Ulcers (DFUs)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
OintmentTopical0.5 g/100g
LiquidTopical0.006 g/6.6g
OintmentTopical1 g/100g
SolutionTopical0.02 mg/71
SolutionTopical0.03 mg/61
CreamTopical0.1 g/50mL
CreamCutaneous0.2 mg/20mL
Powder, for solutionTopical
Paste, dentifriceTopical
Aerosol, sprayTopical0.425 g/85g
OilTopical1 g/108.48g
SprayTopical0.425 g/85g
GelTopical0.5 g/100mL
GelTopical0.15 g/30mL
CreamTopical0.0005 g/1mL
LiquidTopical0.001 g/1mL
CreamTopical0.8 mg/160mL
LotionTopical0.8 mg/160mL
GelTopical0.8 mg/160mL
ShampooTopical1.5 mg/300mL
LotionTopical1.5 g/300mL
ShampooTopical1.5 g/300mL
LiquidTopical0.25 g/100mL
LiquidTopical0.50 g/100mL
LiquidTopical0.15 g/30mL
LiquidTopical0.25 g/50mL
LiquidTopical0.1 g/20mL
SoapTopical0.5 g/100g
LiquidTopical1.0 g/200mL
SolutionTopical0.005 mg/181
LotionTopical0.4 mL/200mL
LiquidTopical0.004 mL/2mL
LiquidTopical0.5 g/100g
PatchTopical0.12 g/60g
ElixirTopical
EmulsionTopical0.6 %
LotionTopical0.25 g/250g
CreamCutaneous0.2 g/40g
PatchTopical0.15 g/31
GelTopical0.15 g/31
PatchTopical0.004 g/2.4g
EmulsionTopical0.1 g/100mL
PatchTopical0.2 g/40g
StickTopical0.5 g/100g
SalveTopical5 mg/1g
LiquidTopical0.15 g/100mL
GelTopical0.55 g/100g
Paste, dentifriceOral
GelTopical0.75 g/75g
CreamTopical0.225 mg/45mL
CreamTopical0.65 mg/130mL
SprayTopical0.6 mg/120mL
CreamTopical0.22 mg/45mL
CreamTopical2 g/100g
PatchTopical0.5 1/25g
PatchTopical0.06 g/51
LiquidTopical0.05 g/100mL
CreamTopical0.5 mg/100g
CreamTopical5 mg/1g
JellyTopical0.5 g/100mL
CreamTopical50 mg/5g
LipstickTopical
GelCutaneous
CreamTopical0.5 mL/100mL
CreamTopical0.5 g/100mL
GelTopical0.2 g/5mL
PowderTopical0.02 g/50g
DiscTopical
Paste, dentifriceDental
EmulsionTopical0.24 g/120mL
EmulsionTopical
PatchTopical0.05 g/25mL
CreamTopical3.6 mL/60mL
LotionTopical0.5 1/50mL
CreamTopical0.5 mg/100mL
GelTopical0.05 g/100g
CreamTopical0.1 g/100g
CreamCutaneous
PatchTopical0.1 g/49g
ShampooTopical6.0 g/300mL
LotionTopical0.75 mg/150mL
GelTopical2 %
LotionTopical2 %
GelTopical0.1 g/100mL
LiquidTopical
LiquidTopical0.1 g/100mL
Powder, dentifriceOral
CreamTopical1 g/50g
SprayTopical0.3 g/60g
SprayTopical1.2 g/100g
Tablet, solubleTopical0.5 mg/100mg
LiquidTopical0.02 g/4mL
LiquidTopical0.19 g/100g
LotionTopical0.5 g/100mL
CreamTopical0.1 g/100mL
PowderTopical0.44 mg/80mL
PowderTopical0.055 g/10g
GelTopical0.8 g/100g
SoapTopical2.0 g/100g
LiquidTopical0.54 mg/90mL
SolutionTopical0.96 g/120mL
SprayTopical0.8 g/100mL
SolutionTopical0.96 mg/120mL
SolutionTopical
LiquidTopical0.1 g/10g
GelTopical0.5 g/100g
OintmentTopical.02 g/1g
CreamTopical10 mg/1g
SolutionTopical0.04 g/5g
CreamTopical20 mg/1g
LotionTopical3 g/600g
LotionCutaneous0.1 mL/20mL
SoapCutaneous; Topical5 mg/1g
PowderTopical0.002 g/1g
SolutionTopical0.25 g/205g
TabletVaginal0.2 1/1
TabletVaginal0.11 1/600mg
TabletVaginal66 mg/600mg
LiquidTopical0.05 g/100g
CreamVaginal
GelExtracorporeal
StickTopical
GelTopical51.0 mg/10mL
GelTopical50 mg/10mL
LiquidCutaneous
GelTopical0.00003 g/10mL
CreamTopical0.67 mg/135mL
CreamTopical0.25 mg/50mL
PatchTopical0.2 g/100g
CreamTopical1 g/100mL
GelTopical10 mg/1mL
GelTopical0.1 mg/1mL
GelTopical1 g/100g
LiquidTopical1 g/100g
CreamTopical
LotionTopical0.55 %
SprayTopical
PatchTopical0.17 mg/35mL
SoapTopical0.6 g/100g
LiquidTopical0.01 g/100mL
OintmentTopical1 %
GelTopical
CreamTopical0.075 g/15mL
LiquidTopical1 mg/30mL
LiquidTopical0.08 g/100mL
LiquidTopical0.75 mg/150mL
PatchTopical0.028 g/28g
SprayTopical0.3 mg/60mL
OilCutaneous
CreamTopical0.5 g/100g
LiquidOphthalmic
Solution / dropsOphthalmic
LiquidTopical0.6 mg/30mL
LiquidTopical0.54 mg/30mL
SoapTopical0.55 g/110g
GelTopical3 mg/1mL
LiquidTopical0.05 g/10mL
ShampooTopical0.75 g/150mL
SolutionTopical0.30 g/60mL
LiquidTopical0.025 g/5mL
LiquidTopical0.0005 g/1mL
SoapTopical1.30 g/100g
PatchCutaneous1.2 mg/20mg
Aerosol, foamTopical1.25 mg/250mL
OilTopical0.75 mg/150mL
GelTopical5 mg/1g
SolutionTopical0.1 g/100mL
EmulsionTopical0.002 g/1mL
CreamTopical1 mg/100mL
LiquidTopical2 g/100mL
Aerosol, foamTopical0.5 g/100mL
LotionTopical0.1 mL/50mL
LiquidTopical0.2 g/100mL
LotionTopical0.4 g/20mL
LiquidTopical0.02 mg/1mL
ClothTopical0.2 g/23mL
LiquidTopical0.1 g/100g
PowderTopical0.007 g/0.7g
ClothTopical0.75 mL/1mL
LiquidTopical1 g/100mL
GelTopical0.05 g/100mL
CreamTopical0.25 g/50g
InjectionTopical
ShampooTopical0.75 mg/150mL
SolutionTopical0.3 mg/60mL
LiquidTopical0.025 mg/5mL
LiquidTopical0.3 g/100mL
SolutionTopical0.175 mg/51
PatchTopical0.16 g/32g
LotionTopical0.1 g/100mL
GelTopical0.00009 g/30mL
PatchTopical0.015 mg/101
SprayTopical0.36 mg/60mL
SprayTopical0.1 g/100mL
CreamTopical0.0125 mg/25g
CreamTopical0.004 mg/20mL
CreamTopical0.0042 mg/21mL
SoapTopical0.05 g/100g
StickTopical5 mg/1g
LotionTopical0.5 mL/100 mL
CreamTopical5 mg/100mL
CreamTopical5 mg/1mL
LotionTopical0.5 mL/100mL
CreamTopical1 g/100g
GelTopical0.3 g/100g
CreamTopical0.005 mg/1g
GelTopical10 mg/1g
CreamTopical1.5 g/300g
LiquidTopical0.48 mg/80mL
SolutionTopical0.48 mg/80mL
CreamTopical0.2 g/100mL
EmulsionTopical0.02 g/100mL
CreamTopical0.02 g/100mL
LiquidTopical0.02 g/100mL
SoapCutaneous5 mg/1g
LotionTopical0.1 g/100g
CreamTopical7.5 mg/1mL
Lotion / shampooTopical5.5 mg/1mL
EmulsionTopical0.55 %
ShampooTopical
GelTopical5 mg/1mL
CreamTopical1.2 g/120mL
Paste, dentifriceDental0.1 mg/100g
LiquidDental0.2 g/100mL
CreamTopical0.28 mg/40mL
CreamTopical1 %
ConcentrateTopical0.22 g/45mL
LiquidTopical0.075 g/15mL
LiquidTopical0.002 mg/1mL
CreamTopical0.000003 g/30mL
LiquidTopical0.002 g/1mL
KitTopical
OintmentTopical
CreamTopical0.002 g/1g
LiquidTopical5 mg/1mL
SolutionTopical1.9 mg/380mL
EmulsionTopical0.65 mg/130mL
CreamTopical0.15 mg/30mL
CreamTopical0.75 mg/150mL
CreamTopical0.1 mL/100mL
CreamTopical0.0075 g/25g
LiquidTopical0.5 g/100mL
LiquidTopical0.625 mg/125mL
LiquidTopical0.57 g/113g
LiquidTopical0.75 g/150g
PatchTopical
CreamTopical0.51 %
PowderTopical0.3 mg/3g
PowderTopical0.003 g/3g
PowderTopical0.2 mg/2g
PowderTopical
LiquidTopical0.1 mg/1mL
MouthwashDental
Gel, dentifriceDental
CreamTopical0.0005 g/1g
PowderTopical0.0001 g/1g
LotionTopical
CreamTopical0.425 g/85mL
CreamTopical0.02 mg/1mL
GelTopical5.5 g/1L
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.73 mg/mLALOGPS
logP-2ALOGPS
logP-2.4Chemaxon
logS-1.5ALOGPS
pKa (Strongest Acidic)7.95Chemaxon
pKa (Strongest Basic)-3.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area113.32 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity32.02 m3·mol-1Chemaxon
Polarizability12.89 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0uds-0911000000-d6d990e16a15b9f27262
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0udi-0920000000-abb5512bfc08cbdd004f
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0f79-0900000000-bf39d4fc494ccd722796
GC-MS Spectrum - GC-MS (5 TMS)GC-MSsplash10-00kr-4911230000-f2112ac79e45fb821ab6
GC-MS Spectrum - GC-MS (4 TMS)GC-MSsplash10-0f8i-3933100000-45367e01790bfc8afd6e
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0zfr-4951100000-88808e71aea4d5ad7885
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0296-9700000000-45ea72c639ca30cd7783
GC-MS Spectrum - EI-BGC-MSsplash10-0006-9100000000-5f4cd23ea44234e5a455
GC-MS Spectrum - EI-BGC-MSsplash10-0006-9100000000-c9c0d8a7f1e5f105a9c3
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0uds-0911000000-d6d990e16a15b9f27262
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0f79-0900000000-bf39d4fc494ccd722796
GC-MS Spectrum - GC-MSGC-MSsplash10-00kr-4911230000-f2112ac79e45fb821ab6
GC-MS Spectrum - GC-MSGC-MSsplash10-0f8i-3933100000-45367e01790bfc8afd6e
GC-MS Spectrum - GC-MSGC-MSsplash10-0zfr-4951100000-88808e71aea4d5ad7885
Mass Spectrum (Electron Ionization)MSsplash10-0006-9200000000-5ad052308edfab7b8c5f
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-02t9-8900000000-bb0a5fee22239a104e6f
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-03dj-9000000000-09992debd5f3d399b902
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-01oy-9000000000-8fe7df22b2abb81b934a
MS/MS Spectrum - EI-B (Unknown) , PositiveLC-MS/MSsplash10-0006-9100000000-08b1881abaf98821d201
MS/MS Spectrum - EI-B (HITACHI M-60) , PositiveLC-MS/MSsplash10-0006-9100000000-297710f62f9699946151
MS/MS Spectrum - DI-ESI-qTof , PositiveLC-MS/MSsplash10-001i-0900000000-54f908cf7928b7fd65c7
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0006-3900000000-4522c35cdff00863fb30
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0006-3900000000-958f71dbb6c860bba8ce
MS/MS Spectrum - , negativeLC-MS/MSsplash10-01ot-7900000000-496295ec2eda1d1fe993
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9100000000-8c779bd6b0021171c0c2
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-1900000000-7a7ef98117854df99d9c
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-1900000000-2559050d81e822a0197d
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000j-1900000000-cba5c4c47b0dac6d035a
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0900000000-cca693ae9b6a97cf20d6
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0aor-0900000000-1643bfc87ee270b781a5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03ds-4900000000-acbaa564c03c640d72fe
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ba-9500000000-46c8f12fe453fbf58b89
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-5f5b2e64087e4f1fc230
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0596-9000000000-e4ead19833ec43f5f55e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-c27bd2f85136491b00c0
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-133.521128
predicted
DarkChem Lite v0.1.0
[M-H]-119.82797
predicted
DeepCCS 1.0 (2019)
[M+H]+134.940328
predicted
DarkChem Lite v0.1.0
[M+H]+123.662994
predicted
DeepCCS 1.0 (2019)
[M+Na]+134.665028
predicted
DarkChem Lite v0.1.0
[M+Na]+132.27083
predicted
DeepCCS 1.0 (2019)

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Major thyroid hormone transport protein in serum.
Gene Name
SERPINA7
Uniprot ID
P05543
Uniprot Name
Thyroxine-binding globulin
Molecular Weight
46324.12 Da
References
  1. CYTOMEL (liothyronine) FDA label [File]

Drug created at December 03, 2015 16:51 / Updated at March 19, 2024 11:06